Yumanity Therapeutics : Dosed First Patient in Phase 1/2 Clinical Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Initial KVA12123 Clinical Data Readout Anticipated by End of 2023 Closed $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - Form 8-K
Dosed First Patient in Phase 1/2 Clinical Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Initial KVA12123 Clinical Data Readout Anticipated by End of 2023 ... | May 11, 2023